HRP20171292T1 - Polipeptidi i konjugati klorotoksina i njihove uporabe - Google Patents
Polipeptidi i konjugati klorotoksina i njihove uporabe Download PDFInfo
- Publication number
- HRP20171292T1 HRP20171292T1 HRP20171292TT HRP20171292T HRP20171292T1 HR P20171292 T1 HRP20171292 T1 HR P20171292T1 HR P20171292T T HRP20171292T T HR P20171292TT HR P20171292 T HRP20171292 T HR P20171292T HR P20171292 T1 HRP20171292 T1 HR P20171292T1
- Authority
- HR
- Croatia
- Prior art keywords
- monoclonal antibody
- seq
- set forth
- antibody according
- fragment
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 11
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 6
- 210000004408 hybridoma Anatomy 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 210000001124 body fluid Anatomy 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 230000008021 deposition Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Psychiatry (AREA)
Claims (26)
1. Izolirano monoklonsko protutijelo, naznačeno time što specifično međudjeluje i pokazuje afinitet od najmanje 106 M–1, kao što je izmjereno površinskom plazmonskom rezonancijom za konformacijski epitop protofibrilnog oblika Aβ peptida, gdje je protofibrilni epitop predstavljan izloženim područjem Aβ-protofibrilnog oblika koji ima aminokiselinski slijed kao što je iznijet u SEQ ID NO:3, dodatno sadrži varijabilni laki lanac koji sadrži područje CDR1 kao što je iznijeto u SEQ ID NO:13, a područje CDR2 kao što je iznijeto u SEQ ID NO:14, te CDR3 kao što je iznijeto u SEQ ID NO:15, zatim varijabilni teški lanac koji sadrži područje CDR1 kao što je iznijeto u SEQ ID NO:20, područje CDR2 kao što je iznijeto u SEQ ID NO:21, te CDR3 kao što je iznijeto u SEQ ID NO:22.
2. Izolirano monoklonsko protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što izloženo područje dodatno sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO:4.
3. Monoklonsko protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što se proizvodi uz pomoć hibridoma dostupnog pod ATCC pristupnim br. PTA-8830.
4. Monoklonsko protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što dodatno sadrži varijabilni laki lanac, koji ima aminokiselinski slijed kao što je iznijet u SEQ ID NO:5, i varijabilni teški lanac, koji ima aminokiselinski slijed kao što je iznijet u SEQ ID NO:7.
5. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačeno time što je protutijelo humanizirano monoklonsko protutijelo.
6. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačeno time što je protutijelo ljudsko monoklonsko protutijelo.
7. Postupak proizvodnje monoklonskog protutijela u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što se sastoji u:
(a) imuniziranju sisavca koji nije čovjek protofibrilnim oblikom β-amiloidnog peptida;
(b) prikupljanju B-stanica iz navedenog sisavca;
(c) stvaranju hibridoma iz prikupljenih B-stanica, gdje navedeni hibridomi proizvode protutijela; i,
(d) odabiru hibridoma koji proizvode protutijela koja se specifično vežu na protofibrilni oblik β-amiloidnog peptida dok pokazuju minimalni afinitet na monomerni ili dimerni oblik β-amiloidnog peptida.
8. Postupak određivanja količine protofibrilnog oblika β-amiloidnog peptida u uzorku tkiva ili tjelesne tekućine, naznačen time što se sastoji u:
(a) dobivanju uzorka tkiva ili tjelesne tekućine iz subjekta;
(b) stavljanju u kontakt uzorka tkiva ili tjelesne tekućine s monoklonskim protutijelom u skladu s bilo kojim od patentnih zahtjeva 1-6, ili njegovim fragmentom koji se specifično veže na protofibrilni oblik β-amiloidnog peptida dok pokazuje minimalni afinitet na niskomolekulske oblike β-amiloidnog peptida; i,
(c) određivanju količine protofibrilnog oblika β-amiloidnog peptida u uzorku.
9. Komplet za detektiranje protofibrilnog oblika β-amiloidnog peptida koji pokazuje veći afinitet na protofibrilni oblik β-amiloidnog peptida nego na niskomolekulski oblik β-amiloidnog peptida, naznačen time što sadrži:
(a) monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, ili njegov fragment, koje se može specifično vezati in vitro na ponavljani konformacijski epitop protofibrilnog oblika β-amiloidnog peptida, dok pokazuje minimalni afinitet na niskomolekulske oblike β-amiloidnog peptida; i,
(b) reagens koji se, izravno ili posredno, veže na navedeno protutijelo ili njegov fragment.
10. Farmaceutski pripravak, koji sadrži (i) monoklonsko protutijelo, ili fragment njegovog varijabilnog područja, u skladu s bilo kojim od patentnih zahtjeva 1-6, koji specifično međudjeluje s protofibrilnim oblikom Aβ-amiloida, te (ii) farmaceutski prihvatljiv nosač, naznačen time što je za navedeno specifično međudjelovanje karakterističan omjer između afiniteta fragmenta s varijabilnim područjem navedenog protutijela prema protofibrilnom obliku Aβ i afiniteta prema drugim oblicima Aβ veći od otprilike 2.
11. Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što je protutijelo monoklonsko protutijelo.
12. Farmaceutski pripravak u skladu s patentnim zahtjevom 10, postupak u skladu s patentnim zahtjevom 7, ili komplet u skladu s patentnim zahtjevom 9, naznačeni time što se protutijelo proizvodi uz pomoć hibridoma dostupnog pod ATCC pristupnim br. PTA-8830.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što je monoklonsko protutijelo humanizirano monoklonsko protutijelo ili ljudsko monoklonsko protutijelo.
14. Hibridom, naznačen time što je dostupan pod ATCC pristupnim br. PTA-8830.
15. Izolirana molekula nukleinske kiseline koja kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što fragment varijabilnog teškog lanca sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO:7.
16. Izolirana molekula nukleinske kiseline koja kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što molekula nukleinske kiseline sadrži nukleotidni slijed kao što je iznijet u SEQ ID NO:8.
17. Ekspresijski vektor, namijenjen eksprimiranju protutijela u skladu s bilo kojim od patentnih zahtjeva 1-6 u rekombinantnoj stanici domaćinu, naznačen time što navedeni ekspresijski vektor sadrži molekulu nukleinske kiseline u skladu s patentnim zahtjevom 15 ili 16.
18. Stanica domaćin uzgojena u kulturi koja eksprimira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što navedena stanica domaćin sadrži ekspresijski vektor u skladu s patentnim zahtjevom 17.
19. Izolirana molekula nukleinske kiseline koja kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što fragment varijabilnog lakog lanca sadrži aminokiselinski slijed kao što je iznijet u SEQ ID NO:5.
20. Izolirana molekula nukleinske kiseline koja kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što molekula nukleinske kiseline sadrži nukleotidni slijed kao što je iznijet u SEQ ID NO:6.
21. Ekspresijski vektor, namijenjen eksprimiranju protutijela u skladu s bilo kojim od patentnih zahtjeva 1-6 u rekombinantnoj stanici domaćinu, naznačen time što navedeni ekspresijski vektor sadrži molekulu nukleinske kiseline u skladu s patentnim zahtjevom 19 ili 20.
22. Stanica domaćin uzgojena u kulturi koja eksprimira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što navedena stanica domaćin sadrži ekspresijski vektor u skladu s patentnim zahtjevom 21.
23. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, ili fragment njegovog varijabilnog područja, namijenjeno upotrebi u liječenju stanja, naznačeno time što je za navedeno stanje karakteristično nastajanje i odlaganje plakova β-amiloidnih vlakana.
24. Farmaceutski djelotvorna količina monoklonskog protutijela, ili njegovog antigenski vežućeg fragmenta, u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačena time što je namijenjena upotrebi u liječenju i/ili sprječavanju odlaganja β-amiloidnog plaka povezanom s početkom i napredovanjem Alzheimerove bolesti.
25. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, ili njegov antigenski vežući fragment, naznačeno time što je namijenjeno upotrebi u liječenju Alzheimerove bolesti.
26. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-6, ili njegov antigenski vežući fragment, naznačeno time što je namijenjeno upotrebi u inhibiranju nastajanja i odlaganja plakova β-amiloidnih vlakana.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98848107P | 2007-11-16 | 2007-11-16 | |
| US1974708P | 2008-01-08 | 2008-01-08 | |
| EP08849467.9A EP2207568B1 (en) | 2007-11-16 | 2008-11-14 | Antibodies specific for the protofibril form of beta-amyloid protein |
| PCT/US2008/083659 WO2009065054A2 (en) | 2007-11-16 | 2008-11-14 | Antibodies specific for the protofibril form of beta-amyloid protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171292T1 true HRP20171292T1 (hr) | 2017-12-15 |
Family
ID=40639468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171292TT HRP20171292T1 (hr) | 2007-11-16 | 2017-08-28 | Polipeptidi i konjugati klorotoksina i njihove uporabe |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US8470321B2 (hr) |
| EP (2) | EP3257865A1 (hr) |
| JP (3) | JP5616230B2 (hr) |
| KR (3) | KR101581733B1 (hr) |
| CN (1) | CN102006887B (hr) |
| AU (1) | AU2008322523B2 (hr) |
| BR (1) | BRPI0819312A2 (hr) |
| CA (1) | CA2705582A1 (hr) |
| CO (1) | CO6270277A2 (hr) |
| CR (1) | CR11350A (hr) |
| CY (1) | CY1119376T1 (hr) |
| DK (1) | DK2207568T3 (hr) |
| DO (1) | DOP2010000097A (hr) |
| EA (1) | EA201000809A1 (hr) |
| ES (1) | ES2639016T3 (hr) |
| HK (1) | HK1244823A1 (hr) |
| HR (1) | HRP20171292T1 (hr) |
| HU (1) | HUE033825T2 (hr) |
| IL (1) | IL204542A (hr) |
| LT (1) | LT2207568T (hr) |
| MA (1) | MA31890B1 (hr) |
| ME (1) | ME01026B (hr) |
| MX (2) | MX2010003828A (hr) |
| MY (1) | MY158903A (hr) |
| NI (1) | NI201000046A (hr) |
| NZ (1) | NZ583632A (hr) |
| PL (1) | PL2207568T3 (hr) |
| PT (1) | PT2207568T (hr) |
| SG (1) | SG2014011183A (hr) |
| SI (1) | SI2207568T1 (hr) |
| TN (1) | TN2010000128A1 (hr) |
| WO (1) | WO2009065054A2 (hr) |
| ZA (1) | ZA201002592B (hr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| KR101413615B1 (ko) | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도 |
| IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
| CN103408661B (zh) * | 2007-01-05 | 2016-04-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
| JP5616230B2 (ja) | 2007-11-16 | 2014-10-29 | ザ ロックフェラー ユニバーシティー | ベータ−アミロイドタンパク質のプロトフィブリルの形態に特異的な抗体 |
| PL2949666T3 (pl) | 2008-12-19 | 2019-07-31 | Biogen International Neuroscience Gmbh | Ludzkie przeciwciała przeciwko alfa-synukleinie |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| US20120100129A1 (en) * | 2009-06-29 | 2012-04-26 | Gellerfors Paer | N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders |
| US10266585B2 (en) | 2009-08-28 | 2019-04-23 | The Board Of Regents Of The Univerity Of Texas System | Methods of treating brain injury |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| EP2595644B1 (en) | 2010-07-23 | 2016-03-30 | Gwangju Institute of Science and Technology | Amyloid-beta clearance |
| EP2627357B1 (en) | 2010-10-15 | 2017-05-03 | The Board of Regents of The University of Texas System | Antibodies that bind amyloid oligomers |
| AR085302A1 (es) | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| SI2723379T1 (sl) | 2011-06-23 | 2019-03-29 | Biogen International Neuroscience Gmbh | Molekule, ki se vežejo ma anti alfa-sinuklein |
| WO2013075740A1 (en) | 2011-11-23 | 2013-05-30 | Sanofi | Antibody purification method |
| JP2013159596A (ja) * | 2012-02-08 | 2013-08-19 | Nihon Univ | β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体 |
| EP2847217B1 (en) | 2012-05-10 | 2017-10-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta |
| EP2674495A1 (en) | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
| HUE057119T2 (hu) | 2013-05-06 | 2022-04-28 | Sanofi Sa | Folyamatos többlépéses eljárás antitestek tisztítására |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| EP3166970B1 (en) * | 2014-07-10 | 2021-03-10 | BioArctic AB | Improved a-beta protofibril binding antibodies |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| WO2017079835A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
| US10774120B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| WO2017079834A1 (en) * | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Epitopes in amyloid beta and conformationally-selective antibodies thereto |
| EP3374379A4 (en) * | 2015-11-09 | 2019-05-15 | The University Of British Columbia | N-TERMINAL EPITOPES IN BETA-AMYLOID AND CONFORMATIONALLY SELECTIVE ANTIBODIES THEREOF |
| DE102016005169B3 (de) | 2016-04-29 | 2017-07-13 | Forschungszentrum Jülich GmbH | Verfahren zur Identifikation von Inhibitoren der primären Nukleation der Amyloid-Beta-Aggregation |
| KR102550991B1 (ko) | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| EP3354278A1 (en) * | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| EA202090555A1 (ru) | 2017-08-22 | 2020-06-08 | Байоджен Ма Инк. | Фармацевтические композиции, содержащие антитела к бета-амилоиду |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US11953502B2 (en) * | 2017-10-12 | 2024-04-09 | E&S Healthcare Co., Ltd. | Thioredoxin 1 epitope, encoding nucleic acid and methods of binding a monoclonal antibody |
| CA3100896C (en) * | 2018-05-30 | 2023-08-29 | National Health Research Institutes | Anti-abeta antibodies and uses thereof |
| CN113474369A (zh) | 2019-01-09 | 2021-10-01 | 维克塔-霍洛斯公司 | 转铁蛋白受体结合分子、其偶联物和它们的用途 |
| TW202110878A (zh) | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
| US20220251518A1 (en) * | 2019-07-08 | 2022-08-11 | Terumo Kabushik Kaisha | Hybridoma, method for making the same, monoclonal antibody, and method for making the same |
| JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2023034324A2 (en) * | 2021-08-30 | 2023-03-09 | The Brigham And Women’S Hospital, Inc. | Methods and materials to treat neurodegenerative disease |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4636524A (en) | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9206318D0 (en) | 1992-03-24 | 1992-05-06 | Cambridge Antibody Tech | Binding substances |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6492160B1 (en) | 1991-05-15 | 2002-12-10 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5962255A (en) | 1992-03-24 | 1999-10-05 | Cambridge Antibody Technology Limited | Methods for producing recombinant vectors |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH09505308A (ja) | 1993-11-19 | 1997-05-27 | アルカーミズ・コントロールド・セラピューティクス・インコーポレイテッド・トゥー | 生物学的活性剤を含有する生分解性微粒子の製造 |
| AU747898B2 (en) | 1997-03-03 | 2002-05-30 | Bristol-Myers Squibb Company | Monoclonal antibodies to human CD6 |
| US6656508B2 (en) | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| JP2001522812A (ja) | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | Ｉｇｆ−１持続放出性処方物の作製方法 |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| US6451346B1 (en) | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
| CA2349434A1 (en) * | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| US6953593B2 (en) | 2000-02-01 | 2005-10-11 | Lipoprotein Technologies, Inc. | Sustained-release microencapsulated delivery system |
| CN101670105B (zh) | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
| EP1284998B1 (en) | 2000-05-22 | 2004-12-29 | New York University | Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク． | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
| US20020192750A1 (en) | 2000-11-15 | 2002-12-19 | Fox Brian A. | Neuropilin homolog zcub5 |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| NZ528957A (en) | 2001-04-18 | 2005-05-27 | Nostrum Pharmaceuticals Inc | A novel coating for a sustained release pharmaceutical composition |
| IL164021A0 (en) * | 2002-03-13 | 2005-12-18 | Univ California | Antibodies and anti-pharmaceutical compositions containing the same |
| WO2003080672A1 (en) | 2002-03-22 | 2003-10-02 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| US8871447B2 (en) * | 2002-09-12 | 2014-10-28 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| US7063725B2 (en) | 2002-10-21 | 2006-06-20 | Sdgi Holdings, Inc. | Systems and techniques for restoring and maintaining intervertebral anatomy |
| US20040223970A1 (en) * | 2003-02-28 | 2004-11-11 | Daniel Afar | Antibodies against SLC15A2 and uses thereof |
| US20050124016A1 (en) * | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
| CA2437639C (en) | 2003-08-11 | 2016-07-05 | Valera Pharmaceuticals, Inc. | Long term drug delivery devices with polyurethane based polymers and their manufacture |
| JP2007527865A (ja) | 2003-09-12 | 2007-10-04 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体 |
| US20050187631A1 (en) | 2004-01-27 | 2005-08-25 | Sdgi Holdings, Inc. | Prosthetic device |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US20110020237A1 (en) | 2005-01-14 | 2011-01-27 | Glabe Charles G | Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| US8124076B2 (en) * | 2005-08-18 | 2012-02-28 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against β-amyloid peptide |
| CN101506236B (zh) * | 2005-11-30 | 2012-12-12 | 雅培制药有限公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
| KR101413615B1 (ko) | 2006-03-23 | 2014-07-18 | 바이오악틱 뉴로사이언스 에이비 | 인간 프로토피브릴에 선택적인 개선된 항체 및 이의 용도 |
| MX2009013505A (es) | 2007-06-12 | 2010-01-27 | Ac Immune Sa | Anticuerpos humanizados para amiloide beta. |
| JP5616230B2 (ja) | 2007-11-16 | 2014-10-29 | ザ ロックフェラー ユニバーシティー | ベータ−アミロイドタンパク質のプロトフィブリルの形態に特異的な抗体 |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
-
2008
- 2008-11-14 JP JP2010534239A patent/JP5616230B2/ja not_active Expired - Fee Related
- 2008-11-14 CA CA2705582A patent/CA2705582A1/en not_active Abandoned
- 2008-11-14 KR KR1020147029636A patent/KR101581733B1/ko active IP Right Grant
- 2008-11-14 EA EA201000809A patent/EA201000809A1/ru unknown
- 2008-11-14 EP EP17173145.8A patent/EP3257865A1/en not_active Withdrawn
- 2008-11-14 BR BRPI0819312-6A patent/BRPI0819312A2/pt not_active Application Discontinuation
- 2008-11-14 MX MX2010003828A patent/MX2010003828A/es active IP Right Grant
- 2008-11-14 EP EP08849467.9A patent/EP2207568B1/en not_active Not-in-force
- 2008-11-14 HU HUE08849467A patent/HUE033825T2/en unknown
- 2008-11-14 SG SG2014011183A patent/SG2014011183A/en unknown
- 2008-11-14 AU AU2008322523A patent/AU2008322523B2/en not_active Ceased
- 2008-11-14 DK DK08849467.9T patent/DK2207568T3/en active
- 2008-11-14 LT LTEP08849467.9T patent/LT2207568T/lt unknown
- 2008-11-14 SI SI200831857T patent/SI2207568T1/sl unknown
- 2008-11-14 KR KR1020107011148A patent/KR101377535B1/ko active IP Right Grant
- 2008-11-14 NZ NZ583632A patent/NZ583632A/en not_active IP Right Cessation
- 2008-11-14 US US12/738,955 patent/US8470321B2/en not_active Expired - Fee Related
- 2008-11-14 KR KR1020137010598A patent/KR101478995B1/ko active IP Right Grant
- 2008-11-14 MX MX2012010835A patent/MX335965B/es unknown
- 2008-11-14 WO PCT/US2008/083659 patent/WO2009065054A2/en active Application Filing
- 2008-11-14 MY MYPI2010001497A patent/MY158903A/en unknown
- 2008-11-14 PT PT88494679T patent/PT2207568T/pt unknown
- 2008-11-14 PL PL08849467T patent/PL2207568T3/pl unknown
- 2008-11-14 CN CN200880116438.9A patent/CN102006887B/zh not_active Expired - Fee Related
- 2008-11-14 ME MEP-2010-76A patent/ME01026B/me unknown
- 2008-11-14 ES ES08849467.9T patent/ES2639016T3/es active Active
-
2010
- 2010-03-16 IL IL204542A patent/IL204542A/en active IP Right Grant
- 2010-03-22 TN TNP2010000128A patent/TN2010000128A1/fr unknown
- 2010-04-07 NI NI201000046A patent/NI201000046A/es unknown
- 2010-04-07 CO CO10039830A patent/CO6270277A2/es not_active Application Discontinuation
- 2010-04-07 CR CR11350A patent/CR11350A/es unknown
- 2010-04-07 DO DO2010000097A patent/DOP2010000097A/es unknown
- 2010-04-14 ZA ZA2010/02592A patent/ZA201002592B/en unknown
- 2010-05-17 MA MA32845A patent/MA31890B1/fr unknown
-
2011
- 2011-01-21 HK HK18104106.3A patent/HK1244823A1/zh unknown
-
2013
- 2013-05-28 US US13/903,081 patent/US9340607B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 JP JP2014135187A patent/JP2014223074A/ja active Pending
-
2016
- 2016-05-16 US US15/155,275 patent/US20160319006A1/en not_active Abandoned
-
2017
- 2017-08-28 HR HRP20171292TT patent/HRP20171292T1/hr unknown
- 2017-08-30 CY CY20171100918T patent/CY1119376T1/el unknown
-
2018
- 2018-03-22 JP JP2018054674A patent/JP2018140988A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171292T1 (hr) | Polipeptidi i konjugati klorotoksina i njihove uporabe | |
| CN110914304B (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| TW201915026A (zh) | Ｔｉｇｉｔ抗體、其抗原結合片段及醫藥用途 | |
| TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
| DK3042917T3 (en) | ANTI-N3PGLU-AMYLOID-BETA-PEPTIDE ANTIBODIES AND APPLICATIONS THEREOF | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| CN107266571A (zh) | 抗‑mcam抗体及相关使用方法 | |
| KR20150038556A (ko) | ＴＮＦ-α 결합 단백질 | |
| JP2019520034A5 (hr) | ||
| JP2014524733A5 (hr) | ||
| US11236155B2 (en) | Antibodies to pyroglutamate amyloid-β and uses thereof | |
| JP2021500916A5 (hr) | ||
| AU2015313179B2 (en) | Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity | |
| JPWO2020004490A5 (hr) | ||
| RU2013114368A (ru) | Пептид или пептидный комплекс, связывающийся с альфа-интегрином, способы его получения и применения указанного вещества | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JPWO2020004492A5 (hr) | ||
| CN113227148B (zh) | 抗gpc3抗体、其抗原结合片段及其医药用途 | |
| CN115298216A (zh) | 抗体或其抗原结合片段、其制备方法及医药用途 | |
| RU2420588C2 (ru) | МЫШИНЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С АНТИГЕНОМ F1 ИЗ Yersinia pestis, СПОСОБ ИХ ПОЛУЧЕНИЯ С ИСПОЛЬЗОВАНИЕМ ДРОЖЖЕЙ, СПОСОБ И НАБОР ДЛЯ ДЕТЕКЦИИ Yersinia pestis | |
| WO2008059616A1 (fr) | Anticorps reconnaissant le domaine c de la midkine | |
| KR101752280B1 (ko) | 영장류 cd154에 특이적인 항체 및 이를 생산하는 융합 세포주 | |
| JP2011050355A (ja) | トランスポーターに対する抗体およびその用途 | |
| WO2022228514A1 (zh) | 抗人白血病抑制因子抗体及其用途 | |
| CN111349169B (zh) | Werner综合征ATP依赖性解旋酶的单克隆抗体及其应用 |